XENCOR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.98 USD | +3.90% |
|
+8.71% | -5.89% |
| 04-16 | BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating | MT |
| 04-09 | Xencor Names Bart Cornelissen as Chief Financial Officer | MT |
| Sales 2024 * | 93.25M 7.47B | Sales 2025 * | 156M 12.48B | Capitalization | 1.23B 98.6B |
|---|---|---|---|---|---|
| Net income 2024 * | -204M -16.33B | Net income 2025 * | -171M -13.69B | EV / Sales 2024 * | 8.1 x |
| Net cash position 2024 * | 476M 38.1B | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.9 x |
| P/E ratio 2024 * |
-5.98
x | P/E ratio 2025 * |
-7.22
x | Employees | 280 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xencor, Inc.
More recommendations
| 1 day | +3.90% | ||
| 1 week | +8.71% | ||
| Current month | -9.72% | ||
| 1 month | -7.20% | ||
| 3 months | -0.50% | ||
| 6 months | +13.59% | ||
| Current year | -5.89% |
1 week
18.06
20.41
1 month
17.9522.70
Current year
17.9526.84
1 year
16.4928.96
3 years
16.4944.68
5 years
16.4958.35
10 years
7.8258.35
| Managers | Title | Age | Since |
|---|---|---|---|
Bassil Dahiyat
FOU | Founder | 53 | 31/07/97 |
John Desjarlais
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/06/01 |
Charles Liles
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Gorman
BRD | Director/Board Member | 66 | 13/04/17 |
| Director/Board Member | 71 | 18/12/17 | |
| Director/Board Member | 70 | 17/03/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.28% | 27 M€ | -5.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 19.98 | +3.90% | 375,500 |
| 25/04/24 | 19.23 | +1.10% | 490,946 |
| 24/04/24 | 19.02 | +3.54% | 763,101 |
| 23/04/24 | 18.37 | +0.88% | 481,161 |
| 22/04/24 | 18.21 | -0.92% | 511,821 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.98
USD
Average target price
36.18
USD
Spread / Average Target
+81.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.89% | 1.23B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- XNCR Stock
